Oncology Drugs Export of Japan: The in-depth Trade Overview of 2024

Oncology drugs are a type of medication used to prevent cancer growth. It is widely demanded among the global consumer base because of its ability to neutralize and reduce the growth of cancerous cells inside the human body. It encompasses a wide range of variants like chemotherapy, drug-targeted therapy, immunotherapy, and hormone therapy. The growing universal demand, accompanied by the limited production sources along with the economic valuation and regulatory standardization, has maintained the continuity in the global trade of oncology medications. Japan Import Data says, the country in East Asia, bordered by Russia and Korea in the north and west direction, are at present influential contributors towards the worldwide export market of oncology medications, mainly due to the strong pharmaceutical research and development investment in Japan and the favourable government export incentives.

The efficient logistics and supply chain, accompanied by the robust insurance and healthcare systems, have maintained the continuity in the solidified global trade rank. The country, with its active participation in global pharmaceutical exports and strict adherence to pharmaceuticals and medical devices, have resulted in a total valuation of exports worth 2.16 billion US dollars in 2024. The patented drugs with global recognition, along with the strong pharmacovigilance and safety monitoring, have been benefiting the overall trade revenue. Subscribe to Import Globals, the leading Japan import export trade provider, to stay updated with the latest information regarding the oncology drugs export of the nation via the Japan trade data.

GOVERNMENT INITIATIVES SUPPORTING THE EXPORT OF ONCOLOGY DRUGS FROM JAPAN IN 2024

The international collaboration of pharmaceuticals and medical devices has sped up the approval and acceptance of the Japanese oncology drugs. The Japan External Trade Organization’s export support programs have connected the Japanese oncology drug manufacturers with overseas buyers.

The AMED funding has accelerated the development of high-value oncology drugs. The regulatory fast track for orphan and cancer drugs has reduced the time to market for new cancer medications.

TOP VARIANTS OF ONCOLOGY DRUGS EXPORTED FROM JAPAN IN 2024

Japan, due to its rising awareness of precision medicine accompanied by the preference for Japanese quality in medical products, has reported a diversity in the global trade output. As per the Japan Export Data, the topmost variants of oncology drugs exported from the nation in 2024 are,

Packaged oncology medicaments — The annual valuation of Packaged oncology medicaments exported from Japan in 2024–824 million US dollars
Doxorubicin — The annual valuation of Doxorubicin exported from Japan in 2024–624 million US dollars
Imatinib — The annual valuation of Imatinib exported from Japan in 2024–544 million US dollars
Tamoxifen — The annual valuation of Tamoxifen exported from Japan in 2024–478 million US dollars
Methotrexate — The annual valuation of Methotrexate exported from Japan in 2024–392 million US dollars
Capecitabine — The annual valuation of Capecitabine exported from Japan in 2024–287 million US dollars
Zanubrutinib — The annual valuation of Zanubrutinib exported from Japan in 2024–221 million US dollars
Erdafitinib — The annual valuation of Erdafitinib exported from Japan in 2024–165 million US dollars
Acalabrutinib — The annual valuation of Acalabrutinib exported from Japan in 2024–124 million US dollars
Monoclonal antibody therapies — The annual valuation of Monoclonal antibody therapies exported from Japan in 2024–98 million US dollars

TOP TRADE PARTNERS OF JAPAN IN 2024

The transparent labelling and documentation of the country, along with the precision medicine capabilities, have maintained the integrity of the nation with the top-most investing regions. According to the Japan Customs Data, the top-most trade partners benefiting the oncology drugs export economy of the nation in 2024 are,

United States — The total valuation of oncology drugs exported from Japan to the United States in 2024–921 million US dollars